within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AD03_Aciclovir;

model Aciclovir
  extends Pharmacolibrary.Drugs.ATC.S.S01AD03
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.2,
    Cl             = 4.388888888888889e-06,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.022,
    k12             = 6.11111111111111e-06,
    k21             = 6.11111111111111e-06
      
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aciclovir</td></tr><tr><td>ATC code:</td><td>S01AD03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>26</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aciclovir is an antiviral medication primarily used for the treatment of herpes simplex virus and varicella-zoster virus infections, including shingles and genital herpes. It is well-established and widely approved for clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose of aciclovir.</p><h4>References</h4><ol><li><p>O&#x27;Brien, JJ, &amp; Campoli-Richards, DM (1989). Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. <i>Drugs</i> 37(3) 233–309. DOI:<a href=\"https://doi.org/10.2165/00003495-198937030-00002\">10.2165/00003495-198937030-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2653790/\">https://pubmed.ncbi.nlm.nih.gov/2653790</a></p></li><li><p>Patel, R (1997). Valaciclovir: development, clinical utility and potential. <i>Expert opinion on investigational drugs</i> 6(2) 173–189. DOI:<a href=\"https://doi.org/10.1517/13543784.6.2.173\">10.1517/13543784.6.2.173</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15989601/\">https://pubmed.ncbi.nlm.nih.gov/15989601</a></p></li><li><p>Noble, S, &amp; Faulds, D (1998). Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. <i>Drugs</i> 56(1) 115–146. DOI:<a href=\"https://doi.org/10.2165/00003495-199856010-00012\">10.2165/00003495-199856010-00012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9664203/\">https://pubmed.ncbi.nlm.nih.gov/9664203</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aciclovir;
